Literature DB >> 2401571

Phase-variable lipopolysaccharide structures enhance the invasive capacity of Haemophilus influenzae.

J N Weiser1, A Williams, E R Moxon.   

Abstract

Genes necessary for the expression and phase variation of lipopolysaccharide epitopes of a virulent Haemophilus influenzae type b isolate (RM.7004) are contained within two chromosomal loci designated lic-1 and lic-2. Mutations were introduced into both lic-1 and lic-2, and the virulence of the double mutant was compared with that of the wild type in infant rats. These mutations in RM.7004 resulted in a significantly reduced incidence of bacteremia following intranasal inoculation, although nasopharyngeal colonization was similar for the mutant and wild-type strains. In contrast, no differences in bacteremia were observed when the mutant and wild-type strains were inoculated intraperitoneally.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2401571      PMCID: PMC313677          DOI: 10.1128/iai.58.10.3455-3457.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Haemophilus influenzae meningitis in infant rats after intranasal inoculation.

Authors:  E R Moxon; A L Smith; D R Averill; D H Smith
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

2.  Defined nongrowth media for stage II development of competence in Haemophilus influenzae.

Authors:  R M Herriott; E M Meyer; M Vogt
Journal:  J Bacteriol       Date:  1970-02       Impact factor: 3.490

3.  Coprecipitation of lipopolysaccharide and the 39,000-molecular-weight major outer membrane protein of Haemophilus influenzae type b by lipopolysaccharide-directed monoclonal antibody.

Authors:  P A Gulig; E J Hansen
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

4.  Nucleotide sequence of the kanamycin resistance transposon Tn903.

Authors:  A Oka; H Sugisaki; M Takanami
Journal:  J Mol Biol       Date:  1981-04-05       Impact factor: 5.469

5.  Characterization of lipopolysaccharide of Haemophilus influenzae.

Authors:  A R Flesher; R A Insel
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

6.  The type b capsular polysaccharide as a virulence determinant of Haemophilus influenzae: studies using clinical isolates and laboratory transformants.

Authors:  E R Moxon; K A Vaughn
Journal:  J Infect Dis       Date:  1981-04       Impact factor: 5.226

7.  Homogeneity of cell envelope protein subtypes, lipopolysaccharide serotypes, and biotypes among Haemophilus influenzae type b from patients with meningitis in The Netherlands.

Authors:  L van Alphen; T Riemens; J Poolman; C Hopman; H C Zanen
Journal:  J Infect Dis       Date:  1983-07       Impact factor: 5.226

8.  Plasmid cloning vectors resistant to ampicillin and tetracycline which can replicate in both E. coli and Haemophilus cells.

Authors:  D B Danner; M L Pifer
Journal:  Gene       Date:  1982-04       Impact factor: 3.688

9.  Electrophoretic heterogeneity and interstrain variation of the lipopolysaccharide of Haemophilus influenzae.

Authors:  T J Inzana
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

10.  Production of Haemophilus influenzae b meningitis in infant rats by intraperitoneal inoculation.

Authors:  A L Smith; D H Smith; D R Averill; J Marino; E R Moxon
Journal:  Infect Immun       Date:  1973-08       Impact factor: 3.441

View more
  26 in total

Review 1.  Phase and antigenic variation in bacteria.

Authors:  Marjan W van der Woude; Andreas J Bäumler
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

2.  The phasevarion: a genetic system controlling coordinated, random switching of expression of multiple genes.

Authors:  Yogitha N Srikhanta; Tina L Maguire; Katryn J Stacey; Sean M Grimmond; Michael P Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-31       Impact factor: 11.205

Review 3.  Phenazines and their role in biocontrol by Pseudomonas bacteria.

Authors:  Thomas F C Chin-A-Woeng; Guido V Bloemberg; Ben J J Lugtenberg
Journal:  New Phytol       Date:  2003-03       Impact factor: 10.151

4.  Identification of a new locus involved in expression of Haemophilus influenzae type b lipooligosaccharide.

Authors:  G P Jarosik; E J Hansen
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

5.  Sporadic invasion of cultured epithelial cells by Haemophilus influenzae type b.

Authors:  P D Johnson; F Oppedisano; V Bennett-Wood; G L Gilbert; R M Robins-Browne
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

6.  Decoration of lipopolysaccharide with phosphorylcholine: a phase-variable characteristic of Haemophilus influenzae.

Authors:  J N Weiser; M Shchepetov; S T Chong
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

7.  Involvement of the Haemophilus ducreyi gmhA gene product in lipooligosaccharide expression and virulence.

Authors:  B A Bauer; M K Stevens; E J Hansen
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Duplicate copies of lic1 direct the addition of multiple phosphocholine residues in the lipopolysaccharide of Haemophilus influenzae.

Authors:  Kate L Fox; Jianjun Li; Elke K H Schweda; Varvara Vitiazeva; Katherine Makepeace; Michael P Jennings; E Richard Moxon; Derek W Hood
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

9.  The tetrasaccharide L-alpha-D-heptose1-->2-L-alpha-D-heptose1--> 3-L-alpha-D-heptose1-->(3-deoxy-D-manno-octulosonic acid) and phosphate in lipid A define the conserved epitope in Haemophilus lipopolysaccharides recognized by a monoclonal antibody.

Authors:  S Borrelli; O Hegedus; D H Shaw; P E Jansson; A A Lindberg
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Identification of a genetic locus of Haemophilus influenzae type b necessary for the binding and utilization of heme bound to human hemopexin.

Authors:  M S Hanson; S E Pelzel; J Latimer; U Muller-Eberhard; E J Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.